Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Sales Boost Ajanta

Company Reports ‘Blowout’ 61% Profit Jump In Q3

Executive Summary

India’s Ajanta Pharma has announced what analysts called “blowout” third-quarter numbers following a string of weaker quarterly performances.

You may also be interested in...

Ajanta Beats Q2 Expectations

India’s Ajanta has reported a 7% drop in second-quarter net profit with its African branded generics remaining a problem area. However, US sales climbed by nearly 40% and analysts remain positive on the company’s outlook, buoyed by a beat on revenue estimates.

Ajanta set to focus on US generics market

Ajanta Pharma’s managing director Yogesh Agrawal has revealed that going forward, the US generics business “will be a key focus market” for the Indian firm. He also reiterated the company’s previous plans to focus on the branded generics business in India and also in Emerging Markets (Generics bulletin, 11 May 2018, page 8).


Gedeon Richter Sees Profit Jump By 40%

A strong tailwind from antipsychotic drug Vraylar helped Hungary’s Gedeon Richter to post a 40% leap in 2019 net profit. Analysts see more upside ahead for eastern Europe’s largest drugmaker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts